vimarsana.com
Home
Live Updates
Higher Fracture Risk Not Seen With SGLT2 Inhibitors : vimars
Higher Fracture Risk Not Seen With SGLT2 Inhibitors : vimars
Higher Fracture Risk Not Seen With SGLT2 Inhibitors
Increased fracture risk seen in short-term studies may have been due to hypovolemia or osmotic diuresis, resulting in falls, rather than an effect on bone.
Related Keywords
United States ,
Canada ,
Netherlands ,
Vancouver ,
British Columbia ,
Maastricht ,
Limburg ,
American ,
Veerle Van Hulten ,
Van Hulten ,
Sarah Berry ,
Drug Administration ,
Maastricht University ,
Society For Bone ,
Marcus Institute For Aging Research ,
Mineral Research ,
Harvard Medical School ,
Marcus Institute ,
Aging Research ,
Fractures ,
Sglt2 Inhibitors ,
Odium Glucose Transporter 2 Inhibitors ,
Odium Glucose Co Transporter 2 Inhibitors ,
Sodium Glucose Cotransporter 2 Inhibitors ,
Diabetes Mellitus Type 2 ,
Iabetes Mellitus Type Ii ,
Type 2 Diabetes ,
Elderly Concerns Of Older Adults ,
Geriatrics Elder Care ,
Osteoporosis ,
Bones ,
Dpp 4 Inhibitors ,
Dipeptidyl Peptidase 4 Inhibitors ,
Minerals ,
Calcium ,
,
Dizziness ,
Fatigue ,
Metabolism ,